Evaxion is halting work on its infectious disease and autoimmune programs and redirecting its R&D efforts solely to oncology. The decision, disclosed in the company’s third-quarter earnings results, makes its phase 2 melanoma vaccine EVX-01 the lead asset in a narrower pipeline built around immuno-oncology.
The company ended September with $13.3 million in the bank and said that cash is expected to last through 2027. CEO Helen Tayton-Martin said on a call with analysts that the change is about maximizing current resources around areas where Evaxion sees engagement and opportunity, making the pipeline shift as much a financing decision as a scientific one.
Pipeline reset
Evaxion’s oncology portfolio includes EVX-01 in phase 2 for advanced melanoma, plus preclinical off-the-shelf vaccines for acute myeloid leukemia and glioblastoma. The company also has a not-yet-disclosed personalized, off-the-shelf vaccine for multiple cancer indications.
The programs being deprioritized include four preclinical infectious disease vaccines aimed at methicillin-resistant Staphylococcus aureus, gonorrhea and cytomegalovirus, as well as an antibody binder and a tolerogenic vaccine for autoimmune indications. Tayton-Martin said Evaxion will finalize the preclinical data packages for the infectious disease assets and actively look for partnerships “where the partner comes forward.” In autoimmune disease, the company said it will continue discovery work and validate the vaccine approach for potential partnering, but the programs will move forward only if a partner is found.
Why oncology now
Evaxion is using its AI-based immunology platform to identify patient-specific antigens and develop immunotherapies. The company is also applying the platform to the dark genome, described as the portion of DNA that does not directly code for proteins, to identify conserved antigens that could support off-the-shelf vaccine opportunities across multiple cancer indications.
The narrower oncology focus follows another portfolio decision in August, when Evaxion scrapped its next-gen solid tumor vaccine to channel resources to a brain cancer candidate being developed with Duke University. More recently, the company reported three-year follow-up data from the phase 2 study of EVX-01 showing 89% vaccine target precision and sustained T-cell and clinical responses.
Management is also framing the repositioning against improving sentiment in personalized cancer vaccines. Tayton-Martin pointed to the recent phase 3 win for Merck & Co. and Moderna in melanoma, saying Evaxion was proud and excited to share its own phase 2 three-year data in recent weeks. The signal for investors is straightforward: Evaxion is no longer trying to prove its platform across several therapeutic areas at once, and its near-term case now depends on whether concentrated oncology spending can create either stronger clinical traction for EVX-01 or partnership demand for the rest of the company’s vaccine technology.




